First UK baby receives Zolgensma on the NHS

1 June 2021

A five-month-old baby has become the first patient to receive Novartis’ (NOVN: VX) Zolgensma (onasemnogene abeparvovec) on the National Health Service (NHS).

Arthur Morgan, who was diagnosed with spinal muscular atrophy (SMA) earlier this month, received the one-off gene therapy at Evelina London Children’s Hospital on May 25.

Zolgensma, which has a list price of £1.8 million ($2.6 million) per single dose, was made available on the NHS following a landmark deal struck with Novartis Gene Therapies in March this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK